Lenalidomide API

Lenalidomide Raw Material is an off‑white to light yellow crystalline powder. It is odorless, bitter in taste with uniform crystal form, featuring excellent flowability. As a highly potent antineoplastic API, our product has a main component content ≥ 99%, with maximum single impurity ≤ 0.10%. Key indicators including residual solvents, heavy metals (Pb, As, Cd, Hg, etc.), elemental impurities, bacterial endotoxins, and microbial limits all exceed international requirements. Our partner factories adopt green synthesis processes, eliminating traditional toxic halogenated reagents. Through one‑pot catalytic coupling and efficient reductive cyclization technologies, the overall yield is increased to above 75%, meeting global environmental standards for pharmaceutical production.

Lenalidomide API is highly targeted and fast‑acting. After oral administration, peak plasma concentration is reached within 0.5-1.5 hours, with a half‑life of 3 hours. Once‑daily dosing maintains effective plasma concentrations. In terms of immunomodulation and resistance reversal, Lenalidomide API reduces pro‑inflammatory factors such as TNF‑α and IL‑6, enhances immune cell cytotoxicity. When combined with chemotherapy, targeted agents, or immune checkpoint inhibitors, it reverses tumor resistance by 4-8 folds, improves chemotherapy efficacy by more than 30%, and reduces cardiac, gastrointestinal, and other chemotherapy‑related toxicities. Lenalidomide API shows no significant nephrotoxicity or hepatotoxicity. Grade 3/4 hematologic adverse reactions are controllable and rapidly relieved by dose adjustment. It does not cause alopecia or severe vomiting typical of conventional chemotherapy, resulting in high patient tolerance and suitability for long‑term use in elderly and frail cancer patients.

We have long‑term supply agreements with multiple GMP, FDA, and CEP certified partner factories, enabling rapid response to urgent and bulk orders. We support R&D pilot trials and large‑volume procurement, with long‑term contract supply to ensure supply chain stability.

Products originate from certified factories with full‑process strict quality inspection. Lenalidomide API purity is stably ≥ 99.0%. Risks including genotoxicity and heavy metals are tightly controlled, providing core assurance for formulation safety and R&D success and helping customers develop high‑quality antineoplastic preparations.

With more than 10 years of global export experience and a complete system of customs declaration, inspection, logistics, and documentation, we can supply Lenalidomide API (CAS 191732-72-6) to over 100 countries and regions including Europe, the United States, Japan, South Korea, Southeast Asia, the Middle East, and South America. We also provide multilingual support that ensures stable replenishment, .

We provide customized services including adjustable particle size, drying method, and packaging specifications. We assist customers in solving technical challenges in formulation R&D, production, and registration.

We have established a 7×12 hour rapid response after‑sales system to promptly address order, logistics, quality, and technical issues, ensuring a worry‑free experience from inquiry, procurement, and receipt to use, providing customers with one‑stop procurement services.